The COVID-19 pandemic drove a large volume of in vitro diagnostic test efforts toward the SARS-CoV-2 virus, such as the Biofire respiratory panel by Biofire Diagnostics LLC, of Salt Lake City, a test for which the U.S. FDA released the special controls.

Privacy legislation was passed and implemented in the European Union, but the picture in the U.S. is pockmarked by state legislation, a scenario that raises concerns about a fractured and impracticable compliance regime.

The $180 million Caresyntax GmbH recently raised in a series C extension round allows the company to accelerate the commercialization and adoption of its precision surgery platform, Bjorn von Siemens, CFO and CBO of Caresyntax told BioWorld.

An implanted deep brain stimulator that calibrates its electrical pulses based on changes in brain activity reduced patients’ most bothersome symptoms of Parkinson’s disease 50%, a small feasibility study published in Nature Medicine found.

Edwards Lifesciences Corp. continued its recent acquisition streak with its buy of JC Medical Inc., a subsidiary of Genesis Medtech International. The sale included the intellectual property and commercial rights for the J-Valve system, a transcatheter aortic valve replacement for the treatment of severe aortic regurgitation.

Less than two months after the June spin-off of Grail Inc. (again), Illumina Inc. revealed a new strategy to cut costs and lift sales growth by focusing on the rapidly evolving multiomics space. Grail, meanwhile, unveiled its own plans to retool, going all in on multi-cancer early detection and cutting headcount 30%.

The World Health Organization has had its collective eye on mpox for some time now, but announced August 14 that the prevalence of the disease in Africa raises the epidemic to a public health emergency of international concern, a change in policy driven by the emergence of a novel strain of the pathogen.